These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29641535)

  • 1. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
    Ku BM; Choi MK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    PLoS One; 2018; 13(4):e0194730. PubMed ID: 29641535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
    Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines.
    Chen T; Luo J; Gu Y; Huang J; Luo Q; Yang Y
    Thorac Cancer; 2019 Apr; 10(4):930-941. PubMed ID: 30883029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
    Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
    Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.
    Tang X; Mu J; Ma L; Tan Q; Wang J; Tan J; Zhang S
    Biochem Biophys Res Commun; 2021 Sep; 571():38-45. PubMed ID: 34303194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
    Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
    Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.
    Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S
    Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
    Eberlein CA; Stetson D; Markovets AA; Al-Kadhimi KJ; Lai Z; Fisher PR; Meador CB; Spitzler P; Ichihara E; Ross SJ; Ahdesmaki MJ; Ahmed A; Ratcliffe LE; O'Brien EL; Barnes CH; Brown H; Smith PD; Dry JR; Beran G; Thress KS; Dougherty B; Pao W; Cross DA
    Cancer Res; 2015 Jun; 75(12):2489-500. PubMed ID: 25870145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
    Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
    J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
    Remon J; Planchard D
    Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
    Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun SY
    Oncogene; 2021 Dec; 40(49):6653-6665. PubMed ID: 34635799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
    Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
    Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
    Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
    Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.